Personalizing cancer care requires detailed information on the distinct genetic traits of an individual’s tumor. In some instances, however, attaining that information through traditional biopsy is not possible. In these instances — such as when tissue is not available for molecular testing, tissue biopsy is not feasible for the patient, biopsy location is difficult, or answers are required quickly — liquid biopsy blood testing can be a viable alternative.
Liquid Biopsy test menu
Noninvasive and highly sensitive, LiquidHALLMARK® uses next-generation sequencing to target both DNA and RNA circulating in the blood to better understand a patient’s cancer. With just one blood draw, this first-in-class offering equips physicians with individualized insights associated with 15 cancers, which enables tailored treatment.
Offered in collaboration with Lucence, the LiquidHALLMARK® assay complements our comprehensive somatic cancer testing menu. Unique to the market, LiquidHALLMARK® sequences circulating RNA and DNA.
Key testing
Advantages
Highlights
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence, to discuss liquid biopsy cancer testing. Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.
Mayo Clinic Laboratories and Lucence are expanding access to advanced cancer testing worldwide with LiquidHALLMARK®, a next-generation liquid biopsy that provides actionable genomic insights. This collaboration empowers physicians to deliver personalized care and improve patient outcomes.